Drug intelligence / Profile preview

s-Amlodipine + Chlorthalidone

Development stage
Unknown
Lead developer
Zydus Lifesciences
Modality
Small Molecules
Administration
Oral
01

Overview

s-Amlodipine + chlorthalidone is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of high blood pressure. s-Amlodipine is the S-enantiomer of amlodipine, a long-acting calcium channel blocker that inhibits L-type calcium channel (Cav1.2) in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption by blocking the Sodium-chloride symporter (SLC12A3) in the distal convoluted tubule of the kidney, resulting in increased excretion of sodium and water, decreased plasma volume, and lowered blood pressure. The combination targets both vascular tone (via s-amlodipine) and fluid balance (via chlorthalidone), providing additive antihypertensive effects[3][4][5][6][8].

Brand names
Amlodac CHAmlong CTEnzochlorAmlovas CH
Other names
amlodipine + chlorthalidones-amlodipine plus chlorthalidone
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on s-Amlodipine + Chlorthalidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on s-Amlodipine + Chlorthalidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call